Revenue down 16.3% on Medicare uncertainty, equity eroded 40.5%

What changed

Operating revenue fell 16.3% to NZ$11.0m from NZ$13.1m, which management attributes to Medicare reimbursement uncertainty and a reduced US sales footprint. Net loss before tax narrowed 4.9% to NZ$14.5m, and with nil tax in both periods NPAT moved in lockstep to the same NZ$14.5m loss. Net operating cash outflow improved to NZ$12.5m from NZ$15.0m, and capex stepped down to NZ$0.5m from NZ$0.8m, leaving pre-lease free cash flow at roughly NZ$13.0m negative versus NZ$15.8m negative. Cash edged up to NZ$21.9m with gross borrowings of only NZ$0.3m, but total equity collapsed 40.5% year-on-year to NZ$40.7m and total assets fell 33.3% to NZ$50.9m, while total liabilities rose 28.2% to NZ$10.2m. Management also notes operating revenue rose 1.4% on 2H24, so the sequential trend is flatter than the HY24 comparison suggests.

What matters

• Top-line compression vs. structurally elevated cash burn. Revenue at NZ$11.0m annualises to NZ$21.9m, still about 8% below FY24's NZ$23.9m, while the half's NZ$13.0m FCF outflow is running at a similar pace to the prior full year's NZ$25.8m operating cash burn. The marginal loss improvement is being driven by cost-out (smaller sales team) rather than scale.
• Equity erosion is the most consequential balance-sheet signal. Total equity fell NZ$27.6m in 12 months while cash only rose NZ$1.5m, implying accumulated losses are compounding faster than the operational improvement. ROE has moved from -22.3% to -35.7%.
• Cash runway is finite and unquantified here. With NZ$21.6m of net cash and a half-yearly burn around NZ$13.0m, the release does not include an explicit runway statement or capital-raise signal for HY25, which is the single most important item not addressed.

Expectations

No forward financial target, revenue guidance, or forward-work metric was disclosed. On shape, HY24 contributed 54.8% of FY24 revenue and 51.6% of FY24 NPAT, so the business is not strongly second-half weighted; the HY25 run-rate therefore cannot lean on a seasonal recovery. Management's own framing that operating revenue is only 1.4% above 2H24 is consistent with stabilisation rather than recovery. The release does not support a thesis that FY25 will recapture FY24's NZ$23.9m revenue base without a rebound in US test volumes.

Quality of result

The narrowing of the loss looks cost-driven rather than operationally durable: revenue is down 16.3% and the stated cause is a deliberately smaller sales team plus Medicare uncertainty, both of which affect the top line more than the bottom line. Cash conversion is not the issue — FCF/NPAT of 89.7% is broadly in line with prior — but the absolute FCF remains heavily negative at NZ$13.0m. Inventories reduced modestly (NZ$1.3m from NZ$1.7m), providing a small working-capital tailwind to operating cash flow. There are no one-off items flagged and no non-GAAP reconciliations to unpick. The underlying read is: a lower cost base producing a slightly smaller loss on lower revenue.

Unresolved

• What is the disclosed cash runway at the current burn rate, and at what point does a capital raise become necessary given equity is down 40.5%?
• What drove the NZ$27.6m equity decline versus only NZ$14.5m of reported loss — is there a reserve movement, buy-back, or other equity impact not captured in the supplied excerpts?
• Is the Medicare reimbursement position expected to resolve in FY25, and what is the volume trajectory ex-US that could offset it?
• With US-dollar ASP and an NZ$0.4m FX impact on cash disclosed, what is the sensitivity of reported revenue to NZD/USD moves?

This briefing cannot assess Pacific Edge's remaining cash runway, clinical reimbursement pipeline, or the specific drivers of the NZ$27.6m year-on-year equity decline beyond the reported loss.

Key metrics

Analytical metrics

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.